I-Mab Announces Upcoming Participation at September Conferences

Author: I-Mab / 2023-07-23 22:06 / Source: I-Mab

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG,Md.,Sept. 8,2020 -- I-Mab (the "Company") (Nasdaq: IMAB),a clinical stage biopharmaceutical company committed to the discovery,development and commercialization of novel biologics,today announced its participation in the following conferences in September. Details of the conferences and management presentations are as follows:

Cantor Fitzgerald Virtual Global Healthcare Conference 2020

Presentation: Tuesday,September 15,2020 at 8:00-8:30 a.m. ET

Presenters:Dr. Jingwu Zang,Founder,Honorary Chairman and Director,Dr. Joan Huaqiong Shen,Director and Chief Executive Officer,Mr. Jielun Zhu,Director and Chief Financial Officer,and Ms. Leah Liu,Senior IR Director

Webcast link: https://www.webcaster4.com/Webcast/Page/2495/37179

The webcast will alsobe available under "Event Calendar" on IMAB's IR website at https://ir.i-mabbiopharma.com/

One-on-one meetings: September 15-17,2020

For more information,please contact your Cantor Fitzgerald representative.

Jefferies Virtual Asia Forum

Presentation: Wednesday,September 16,2020 at 4:00-4:50 a.m. ET

Presenters:Dr. Jingwu Zang,Senior IR Director

One-on-one and small group meetings: September14-16,please contact your Jefferies representative.

ICBCI VirtualADR New Economy Conference

Management participants: Dr. Jingwu Zang,Senior IR Director

One-on-one and small group meetings: September18,please contact your ICBCIrepresentative.

2020 Huatai USA Autumn Virtual China Conference

Management participants: Dr. Jingwu Zang,Senior IR Director

One-on-one and small group meetings: September21-23,please contact your Huatairepresentative.

Morgan Stanley Virtual Asia Pacific Conference

Management participants: Dr. Jingwu Zang,Senior IR Director

One-on-one and small group meetings: September24-25,please contact your Morgan Stanleyrepresentative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic,global biotech company exclusively focused on discovery,development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities,world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing,Shanghai,Hong Kong and Maryland,United States. For more information,please visit http://ir.i-mabbiopharma.com

For more information,please contact:

I-Mab

Jielun Zhu,CFO

E-mail: jielun.zhu@i-mabbiopharma.com

Office line: +86 21 6057 8000

Gigi Feng,Vice President and Global Head of Corporate Communications

E-mail: gigi.feng@i-mabbiopharma.com

Office line: +86 21 6057 8000

Investor Inquiries:

Burns McClellan,Inc. (Americas and Europe)

Steve Klass

E-mail: sklass@burnsmc.com